The biotechnology sector, as an investment vehicle, is a high risk endeavor. Whether a company operates in the pre-clinical phases, or is an active member of the "Big Pharma Fraternity", the exposure to potential project failure is considerable. Admittedly, the superior resources of larger and more established entities provide greater downside protection. However, regardless of an entities market capitalization and financial strength, all biotechnology companies are subject to rigorous oversight, laborious processes, and FDA evaluation. Thus, in context, all biotechnology enterprises are faced with the same arduous journey.
One such company, currently devoted to making this often treacherous expedition, is Stellar Biotechnologies (OTCQB:SBOTF). Stellar is, arguably, the world leader in both research, and sustainable development of, ...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|